Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Common Equity (2020 - 2025)

Historic Common Equity for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to -$2.1 million.

  • HCW Biologics' Common Equity rose 7886.38% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 7886.38%. This contributed to the annual value of -$6.8 million for FY2024, which is 15029.2% down from last year.
  • Latest data reveals that HCW Biologics reported Common Equity of -$2.1 million as of Q3 2025, which was up 7886.38% from -$51972.0 recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Common Equity peaked at $54.0 million during Q3 2021, and registered a low of -$23.2 million during Q2 2021.
  • In the last 5 years, HCW Biologics' Common Equity had a median value of $18.7 million in 2023 and averaged $18.4 million.
  • As far as peak fluctuations go, HCW Biologics' Common Equity soared by 40620.9% in 2021, and later plummeted by 19795.72% in 2025.
  • Quarter analysis of 5 years shows HCW Biologics' Common Equity stood at $51.2 million in 2021, then decreased by 26.89% to $37.4 million in 2022, then plummeted by 64.03% to $13.5 million in 2023, then tumbled by 150.29% to -$6.8 million in 2024, then surged by 68.88% to -$2.1 million in 2025.
  • Its Common Equity stands at -$2.1 million for Q3 2025, versus -$51972.0 for Q2 2025 and -$8.6 million for Q1 2025.